Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Imaging Guidelines and Treatment Strategies for Digestive System Diseases
share announcement

Clinical Imaging Guidelines and Treatment Strategies for Digestive System Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 1259

Special Issue Editor

Dr. Rachel Gingold-Belfer

E-Mail
Guest Editor
Gastroenterology Division, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel
Interests: celiac disease; GERD; liver; IBD; imaging; GI

Special Issue Information

Dear Colleagues,

Gastrointestinal diseases constitute hugely diverse disorders related to the liver, pancreas, bile tract, esophagus, stomach, small bowel, and colon. In recent years, an enormous progression in the diagnosis and treatment of gastrointestinal diseases has occurred due to the development of new instruments and technological methods, such as Fibroscan instead of liver biopsy for the evaluation of liver fibrosis in Hepatitis C, mechanical devices for the treatment of gastroesophageal reflux disease (GERD), using fecal microbiota for the treatment of Clostridium difficile, and so on.  The aim of this issue is to provide a platform for clinical research and clinicians in the field of gastrointestinal diseases to publish their research findings and updated reviews on topics related to the diagnosis and treatment of gastrointestinal diseases. Papers on treatments for GERD and their impact, the diagnosis of liver diseases, small bowel US for IBD evaluation, the impact of GFD for CD, etc., are invited.

Dr. Rachel Gingold-Belfer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • celiac disease
  • GERD
  • liver
  • IBD
  • imaging
  • GI

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2102 KiB  
Article
A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis
by Yuchul Jeong, Beom Jun Lee and Se-Hyeon Han
J. Clin. Med. 2024, 13(11), 3262; https://doi.org/10.3390/jcm13113262 - 31 May 2024
Abstract
Background: Fexuprazan (Fexuclue®; Daewoong Pharmaceutical Co., Ltd., Seoul, Korea) is a novel potassium-competitive acid blocker (P-CAB). This multi-center, randomized, double-blind, active-controlled, parallel-group, therapeutic confirmatory, phase III study was conducted to assess its efficacy and safety compared with esomeprazole (Nexium®; [...] Read more.
Background: Fexuprazan (Fexuclue®; Daewoong Pharmaceutical Co., Ltd., Seoul, Korea) is a novel potassium-competitive acid blocker (P-CAB). This multi-center, randomized, double-blind, active-controlled, parallel-group, therapeutic confirmatory, phase III study was conducted to assess its efficacy and safety compared with esomeprazole (Nexium®; AstraZeneca, Gothenburg, Mölndal, Sweden) in Korean patients with erosive esophagitis (EE). Methods: This study evaluated patients diagnosed with EE at a total of 25 institutions in Korea between 13 December 2018 and 7 August 2019. After voluntarily submitting a written informed consent form, the patients were evaluated using a screening test and then randomized to either of the two treatment arms. The proportion of the patients who achieved the complete recovery of mucosal breaks at 4 and 8 weeks, the proportion of those who achieved the complete recovery of heartburn at 3 and 7 days and 8 weeks, and changes in the GERD–Health-Related Quality of Life Questionnaire (GERD-HRQL) scores at 4 and 8 weeks from baseline served as efficacy outcome measures. The incidence of treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs) and the serum gastrin levels served as safety outcome measures. Results: The study population comprised a total of 231 patients (n = 231) with EE, including 152 men (65.80%) and 79 women (34.20%); their mean age was 54.37 ± 12.66 years old. There were no significant differences in the efficacy and safety outcome measures between the two treatment arms (p > 0.05). Conclusions: It can be concluded that the efficacy and safety of Fexuclue® are not inferior to those of esomeprazole in Korean patients with EE. Full article
(This article belongs to the Special Issue Clinical Imaging Guidelines and Treatment Strategies for Digestive System Diseases)
13 pages, 1308 KiB  
Article
Diagnosis, Clinical Presentation and Management of Celiac Disease in Children and Adolescents in Poland
by Joanna B. Bierła, Anna Szaflarska-Popławska, Urszula Grzybowska-Chlebowczyk, Beata Oralewska, Marta Cyba, Grzegorz Oracz, Ewa Konopka, Bożena Cukrowska, Małgorzata Syczewska, Honorata Kołodziejczyk, Petra Rižnik and Jernej Dolinšek
J. Clin. Med. 2024, 13(3), 765; https://doi.org/10.3390/jcm13030765 - 29 Jan 2024
Viewed by 1032
Abstract
Celiac disease (CD) is a chronic immune-mediated disorder triggered by the ingestion of gluten in genetically predisposed individuals, affecting about 1% of the general population in the developed world. In 2012, the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) recommendations for [...] Read more.
Celiac disease (CD) is a chronic immune-mediated disorder triggered by the ingestion of gluten in genetically predisposed individuals, affecting about 1% of the general population in the developed world. In 2012, the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) recommendations for CD diagnoses in children and adolescents were introduced, allowing the “no-biopsy” approach if certain criteria were met. This approach was also confirmed in the revised guidelines published in 2020. Thus, the aim of this study was to assess—over a one-year period—the clinical presentations and current status of the management of children and adolescents diagnosed with CD in Poland. Medical records of children and adolescents, newly diagnosed with CD in 2022/2023 in three medical centers in Poland, were involved. Gastroenterologists completed the specific anonymous web-based forms developed in the CD SKILLS project, including data routinely assessed at individual visits about the diagnostic approach and clinical presentation of the disease. Our study assessed 100 patients (56% girls) with an age range 1.6–18.0 years. We found that 98% of patients were serologically tested prior to a CD diagnosis and 58% of patients were diagnosed using the “no-biopsy” approach. In the analyzed group, 40% belonged to a known risk group, only 22% had annual screening before the CD diagnosis (the longest for 9 years), and 19% showed no symptoms at the time of the CD diagnosis. Our research confirmed the applicability of the “no-biopsy” approach for the diagnosis of CD in children and adolescents in Poland, and also showed changes in the clinical picture of CD. Moreover, we highlight the need to introduce broad CD serological screening in risk groups of the Polish population. Full article
(This article belongs to the Special Issue Clinical Imaging Guidelines and Treatment Strategies for Digestive System Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop